FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2751837787> ?p ?o ?g. }

• W2751837787 endingPage "1721" @default.
• W2751837787 startingPage "1714" @default.
• W2751837787 abstract "Nicotinamide phosphoribosyltransferase (NAMPT) and nicotinic acid phosphoribosyltransferase (NAPRT) are rate-limiting enzymes in the NAD+ synthesis pathway. Chondrosarcoma is a malignant cartilage forming bone tumor, in which mutations altering isocitrate dehydrogenase-1 and -2 (IDH1 and IDH2) activity have been identified as potential driver mutations. Vulnerability for NAD+ depletion has been reported for IDH1/2-mutant cells. Here, the potency of NAMPT inhibitors as a treatment of chondrosarcoma was explored. Eleven chondrosarcoma cell lines were treated with NAMPT inhibitors, in which the effect on cell viability, colony formation, and 3D collagen invasion was assessed. The expression level of NAMPT and NAPRT transcripts in chondrosarcoma cells was determined by qRT-PCR. Methylation of the NAPRT promoter was evaluated using a previously published dataset of genome-wide methylation. In addition, a methylation dataset was used to determine methylation of the NAPRT promoter in 20 IDH1/2-mutated cartilage tumors. Chondrosarcoma cells showed a dose-dependent decrease in cell viability, 3D collagen invasion, and colony formation upon treatment with NAMPT inhibitors, in which nearly half of the cell lines demonstrated absolute IC50s in the low nanomolar range. Increasing IC50s correlated to increasing NAPRT expression levels and decreasing NAPRT promoter methylation. No correlation between IDH1/2 mutation status and sensitivity for NAMPT inhibitors was observed. Strikingly, higher methylation of the NAPRT promoter was observed in high-grade versus low-grade chondrosarcomas. In conclusion, this study identified NAMPT as a potential target for treatment of chondrosarcoma.Implications: Chondrosarcoma patients, especially those of high histologic grade with lower expression and hypermethylation of NAPRT, may benefit from inhibition of the NAD synthesis pathway. Mol Cancer Res; 15(12); 1714-21. ©2017 AACR." @default.
• W2751837787 created "2017-09-15" @default.
• W2751837787 creator A5002809524 @default.
• W2751837787 creator A5035976720 @default.
• W2751837787 creator A5037747325 @default.
• W2751837787 creator A5039831424 @default.
• W2751837787 creator A5046390152 @default.
• W2751837787 creator A5065611045 @default.
• W2751837787 creator A5066142399 @default.
• W2751837787 creator A5082735106 @default.
• W2751837787 creator A5083401778 @default.
• W2751837787 date "2017-11-30" @default.
• W2751837787 modified "2023-10-13" @default.
• W2751837787 title "NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma" @default.
• W2751837787 cites W1481822065 @default.
• W2751837787 cites W1782672155 @default.
• W2751837787 cites W1934866169 @default.
• W2751837787 cites W1953904757 @default.
• W2751837787 cites W1985075679 @default.
• W2751837787 cites W1985167677 @default.
• W2751837787 cites W1990759223 @default.
• W2751837787 cites W2004673921 @default.
• W2751837787 cites W2005165035 @default.
• W2751837787 cites W2011376261 @default.
• W2751837787 cites W2013768145 @default.
• W2751837787 cites W2023851252 @default.
• W2751837787 cites W2065106750 @default.
• W2751837787 cites W2071426227 @default.
• W2751837787 cites W2072658176 @default.
• W2751837787 cites W2081182312 @default.
• W2751837787 cites W2086612689 @default.
• W2751837787 cites W2094851085 @default.
• W2751837787 cites W2108994338 @default.
• W2751837787 cites W2119700304 @default.
• W2751837787 cites W2121640742 @default.
• W2751837787 cites W2125221126 @default.
• W2751837787 cites W2127431419 @default.
• W2751837787 cites W2131860315 @default.
• W2751837787 cites W2132834292 @default.
• W2751837787 cites W2135571996 @default.
• W2751837787 cites W2138320521 @default.
• W2751837787 cites W2139320630 @default.
• W2751837787 cites W2150312029 @default.
• W2751837787 cites W2155106329 @default.
• W2751837787 cites W2158900087 @default.
• W2751837787 cites W2161009819 @default.
• W2751837787 cites W2192221936 @default.
• W2751837787 cites W2194358780 @default.
• W2751837787 cites W2519170380 @default.
• W2751837787 cites W2611221742 @default.
• W2751837787 doi "https://doi.org/10.1158/1541-7786.mcr-17-0293" @default.
• W2751837787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28860121" @default.
• W2751837787 hasPublicationYear "2017" @default.
• W2751837787 type Work @default.
• W2751837787 sameAs 2751837787 @default.
• W2751837787 citedByCount "32" @default.
• W2751837787 countsByYear W27518377872018 @default.
• W2751837787 countsByYear W27518377872019 @default.
• W2751837787 countsByYear W27518377872020 @default.
• W2751837787 countsByYear W27518377872021 @default.
• W2751837787 countsByYear W27518377872022 @default.
• W2751837787 countsByYear W27518377872023 @default.
• W2751837787 crossrefType "journal-article" @default.
• W2751837787 hasAuthorship W2751837787A5002809524 @default.
• W2751837787 hasAuthorship W2751837787A5035976720 @default.
• W2751837787 hasAuthorship W2751837787A5037747325 @default.
• W2751837787 hasAuthorship W2751837787A5039831424 @default.
• W2751837787 hasAuthorship W2751837787A5046390152 @default.
• W2751837787 hasAuthorship W2751837787A5065611045 @default.
• W2751837787 hasAuthorship W2751837787A5066142399 @default.
• W2751837787 hasAuthorship W2751837787A5082735106 @default.
• W2751837787 hasAuthorship W2751837787A5083401778 @default.
• W2751837787 hasBestOaLocation W27518377871 @default.
• W2751837787 hasConcept C104317684 @default.
• W2751837787 hasConcept C127848430 @default.
• W2751837787 hasConcept C142724271 @default.
• W2751837787 hasConcept C143065580 @default.
• W2751837787 hasConcept C153911025 @default.
• W2751837787 hasConcept C181199279 @default.
• W2751837787 hasConcept C185592680 @default.
• W2751837787 hasConcept C2776059313 @default.
• W2751837787 hasConcept C2776302905 @default.
• W2751837787 hasConcept C2777150147 @default.
• W2751837787 hasConcept C2780391879 @default.
• W2751837787 hasConcept C33288867 @default.
• W2751837787 hasConcept C502942594 @default.
• W2751837787 hasConcept C53227056 @default.
• W2751837787 hasConcept C54355233 @default.
• W2751837787 hasConcept C55493867 @default.
• W2751837787 hasConcept C71924100 @default.
• W2751837787 hasConcept C75520062 @default.
• W2751837787 hasConcept C81885089 @default.
• W2751837787 hasConcept C86803240 @default.
• W2751837787 hasConceptScore W2751837787C104317684 @default.
• W2751837787 hasConceptScore W2751837787C127848430 @default.
• W2751837787 hasConceptScore W2751837787C142724271 @default.
• W2751837787 hasConceptScore W2751837787C143065580 @default.
• W2751837787 hasConceptScore W2751837787C153911025 @default.

• next